PTPRC and plasma cell myeloma: For instance, from a clinical decision-making point of view, IPT has enabled cellular monitoring to detect signs of disease aggravation such as the absence of CD45 expression in MM (28), the overexpression of FOXP3 and CTLA4 in the BM (31), and the overexpression of CD229 on myeloma clonogenic precursors (32).